Table 2 Cumulative-incidence-rates and median times to first detection of general outcome and infection data

General outcome

Death

1.7 [1.10;2.80]

18

141 (66–275)

Graft loss

2.3 [1.60;3.50]

24

155 (82–223)

Biopsy proven acute rejection (all)

21.4 [18.90;24.00]

218

90 (30–163)

Biopsy proven acute rejection (without borderline)

10.0 [8.30;12.00]

101

133 (77–187)

T-cell mediated rejection

9.5 [7.90;11.50]

97

135 (78–188)

 Banff IA

3.5 [2.50;4.80]

34

121 (86–182)

 Banff IB

1.2 [0.70;2.20]

12

130 (92–184)

 Banff IIA

3.8 [2.70;5.20]

37

135 (77–185)

 Banff IIB

1.2 [0.70;2.20]

12

102 (70–168)

 Banff III

0.2 [0.10;0.80]

2

143 (139-147)

Antibody-mediated rejection

0.7 [0.03;0.015]

7

189 (100–271)

Borderline rejection

14.2 [12.2;16.5]

147

79 (20–138)

Infections

Herpes/Polyomaviruses

26.6 [24.1;29.4]

269

119 (76–188)

Herpesviruses

16.7 [14.6;19.2]

169

129 (71–208)

 CMV

14.3 [12.3;16.6]

144

138 (77–219)

 D+/R-

28.6 [22.9;35.6]

57

119 (90–160)

 D+/R+

13.6 [10.4;17.8]

46

176 (117–255)

D-/R+

15.1 [10.8;21.0]

30

131 (56–181)

 D-/R-

1.8 [0.7;4.8]

4

94 (38–167)

Other herpesviruses

3.0 [2.2;4.3]

31

90 (45–145)

 HSV-1

1.5 [0.9;2.5]

15

90 (42–148)

 VZV

0.9 [0.5;1.7]

9

93 (53–152)

 HSV-2

0.6 [0.3;1.3]

6

90 (60–180)

 EBV

0.7 [0.3;1.4]

7

123 (95–158)

 HHV-6

0.1 -

1

-

Polyomaviruses

13.2 [11.2;15.4]

132

108 (78–174)

BKV

13.2 [11.2;15.4]

132

108 (78–174)

JCV

0.1 [-]

1

-

Other infections

Bacterial infection

41.7 [38.8;44.8]

428

30 (10–85)

Fungal infection

4.7 [3.6;6.2]

48

52 (17–140)